The board’s annual report for 2023 shows that its budget and staff are 56 per cent and 18 per cent, respectively, above their ...

Even well-known drugs can cause entirely unpredictable effects on metabolism, Swiss researchers have shown. Rapidly mapping ...

Immunotherapeutics have transformed cancer outcomes. It is crucial that response patterns seen with them are assessed ...

Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities ...

China, one of the countries affected by the new tariffs, is the world’s largest producer of active pharmaceutical ingredients ...

Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at leveraging advanced analytics and knowledge graph AI to drive innovation in Pfizer’s drug discovery and development ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.

The guidance would require drug and device makers to set goals and detail their strategies for enrolling people from diverse populations ... understanding of drug responses and safety for all ...